Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Inclusion Criteria: * Histologically or cytologically confirmed advanced (stage IIIB) or metastatic (stage IV) NSCLC; * ALK positive with TP53 mutation was confirmed by tissue samples or blood in each center; TP53 mutation detection needs to be confirmed by NGS. ALK positive can be detected by NGS,IHC,RT-PCR and FISH; * Age ≥ 18 years old; * ALK-TKI-naive patients, and allowed to have received at most one line previous chemotherapy; * ECOG Performance status (PS) score is 0-2; * Karnofsky Performance Status of ≥70; * Subjects with CNS metastases are only eligible if the CNS metastases are adequately treated with radiotherapy and/or surgery and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 1 week prior to randomization. A.Patients receiving radiotherapy or radiosurgery with a dose exceeding 30 Gy will have 3 weeks for neurological stabilization before randomization. B.This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. * Life expectancy of at least 12 weeks; * Able to swallow oral drugs; * It has certain organ system functions, defined as follows: A. Absolute neutrophil count (ANC) ≥1.5 x 109/L B. Platelets ≥100 x 109/L C. hemoglobin ≥9 g per deciliter (≥90g per liter) note that blood transfusions are permitted to achieve the required hemoglobin level. D. Total bilirubin ≤1.5 times upper limit of normal (ULN) E. In the absence of l…